Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 5.1%

Shares of Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) rose 5.1% on Monday . The company traded as high as $1.45 and last traded at $1.45, approximately 821,700 shares changed hands during trading. An increase of 89% from the average daily volume of 433,856 shares. The stock had previously closed at $1.38.

EYPT has been the topic of a number of analyst reports. ValuEngine cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. HC Wainwright cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, November 11th. Guggenheim initiated coverage on shares of Eyepoint Pharmaceuticals in a research report on Thursday, September 12th. They set a “buy” rating and a $4.00 price objective on the stock. Laidlaw initiated coverage on shares of Eyepoint Pharmaceuticals in a research report on Monday, November 4th. They set a “buy” rating and a $5.00 price objective on the stock. Finally, B. Riley cut their price objective on shares of Eyepoint Pharmaceuticals from $5.75 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, September 24th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $3.95.

The stock has a market capitalization of $153.53 million, a PE ratio of -2.50 and a beta of 1.79. The company has a quick ratio of 4.29, a current ratio of 4.54 and a debt-to-equity ratio of 3.12. The stock’s 50 day moving average price is $2.03 and its 200-day moving average price is $1.70.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its earnings results on Thursday, November 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.01). The company had revenue of $2.51 million for the quarter, compared to analysts’ expectations of $4.81 million. Eyepoint Pharmaceuticals had a negative net margin of 409.07% and a negative return on equity of 250.32%. As a group, sell-side analysts predict that Eyepoint Pharmaceuticals Inc will post -0.54 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Creative Planning purchased a new stake in shares of Eyepoint Pharmaceuticals during the third quarter valued at $47,000. River & Mercantile Asset Management LLP purchased a new stake in shares of Eyepoint Pharmaceuticals during the second quarter valued at $1,435,000. Jane Street Group LLC boosted its stake in shares of Eyepoint Pharmaceuticals by 1,682.6% during the second quarter. Jane Street Group LLC now owns 202,580 shares of the company’s stock valued at $332,000 after purchasing an additional 191,216 shares during the period. Essex Woodlands Management Inc. purchased a new stake in shares of Eyepoint Pharmaceuticals during the second quarter valued at $68,731,000. Finally, BlackRock Inc. boosted its stake in shares of Eyepoint Pharmaceuticals by 298.2% during the second quarter. BlackRock Inc. now owns 4,635,930 shares of the company’s stock valued at $7,602,000 after purchasing an additional 3,471,613 shares during the period. 56.84% of the stock is owned by hedge funds and other institutional investors.

About Eyepoint Pharmaceuticals (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.

Further Reading: Most Active Stocks: Dollar Volume vs Share Volume

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.